Enzastaurin

Generic Name
Enzastaurin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C32H29N5O2
CAS Number
170364-57-5
Unique Ingredient Identifier
UC96G28EQF
Background

Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

Indication

Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

First Posted Date
2022-07-19
Last Posted Date
2024-03-08
Lead Sponsor
Aytu BioPharma, Inc.
Target Recruit Count
260
Registration Number
NCT05463679
Locations
πŸ‡ΊπŸ‡Έ

Aytu BioPharma, Englewood, Colorado, United States

A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Phase 1
Completed
Conditions
Solid Tumor
Lymphoma, Malignant
Interventions
Drug: Enzastaurin
First Posted Date
2011-09-13
Last Posted Date
2020-10-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
26
Registration Number
NCT01432951
Locations
πŸ‡¨πŸ‡³

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

First Posted Date
2011-07-06
Last Posted Date
2020-07-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
13
Registration Number
NCT01388335
Locations
πŸ‡«πŸ‡·

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France

A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

Phase 2
Completed
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Drug: Enzastaurin
First Posted Date
2008-09-01
Last Posted Date
2020-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
25
Registration Number
NCT00744991
Locations
πŸ‡ΊπŸ‡Έ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

First Posted Date
2008-07-18
Last Posted Date
2020-09-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
56
Registration Number
NCT00718419
Locations
πŸ‡«πŸ‡·

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France

A Study for Participants With Metastatic Renal Cell Carcinoma

First Posted Date
2008-07-03
Last Posted Date
2019-09-30
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
17
Registration Number
NCT00709995
Locations
πŸ‡΅πŸ‡±

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

First Posted Date
2008-02-11
Last Posted Date
2020-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
117
Registration Number
NCT00612586
Locations
πŸ‡΅πŸ‡·

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

First Posted Date
2008-01-04
Last Posted Date
2020-09-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
81
Registration Number
NCT00586508
Locations
πŸ‡ΊπŸ‡Έ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States

A Study for Patients With Non-Hodgkin's Lymphomas

Phase 2
Completed
Conditions
B-Cell Lymphoma
T-Cell Lymphoma
Interventions
Drug: enzastaurin
First Posted Date
2007-10-12
Last Posted Date
2020-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
57
Registration Number
NCT00542919
Locations
πŸ‡΅πŸ‡ͺ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lima, Peru

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

First Posted Date
2007-10-03
Last Posted Date
2020-11-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
35
Registration Number
NCT00538681
Locations
πŸ‡·πŸ‡΄

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy